Essential Pharma has joined forces with German pharmaceutical company Nordmark Pharma to bring a pancreatic enzyme replacement therapy (PERT) to eligible patients in the UK, marking a significant step in expanding treatment options for people living with pancreatic exocrine insufficiency.

 

Under the partnership, UK-headquartered Essential Pharma will commercialise Nordmark’s pancreas powder 25,000 gastro-resistant capsules in the UK.

 

The move combines Nordmark’s more than 50 years of experience in developing, manufacturing and marketing pancreatic extract with Essential Pharma’s over 40 years of experience providing specialist treatments in the UK.

 

The newly available medicine is indicated for the treatment of pancreatic exocrine insufficiency, a condition in which the pancreas fails to produce sufficient digestive enzymes to break down food. The condition can be associated with serious illnesses, including cystic fibrosis, chronic pancreatitis and pancreatic cancer.

 

The partnership brings together complementary expertise in pancreatic enzymes, with Essential Pharma drawing on its UK-based medical, quality and pharmacovigilance teams to support the medicine's availability to eligible patients.

 

Becki Morison, Chief Executive Officer of Essential Pharma, commented: “People living with complex conditions such as pancreatic exocrine insufficiency, and their healthcare teams, need confidence in the company behind their medicine. Our partnership with Nordmark brings together its long experience in manufacturing pancreatic enzymes with our own experience of cystic fibrosis care and pancreatic enzyme replacement therapy in the UK. It reflects how Essential Pharma works: choosing our partners carefully and committing to the patients we serve for the long term.”

 

Jörn Tonne, Chief Executive Officer of Nordmark, said: “Pancreatic enzymes have been at the heart of Nordmark for more than five decades. Receiving marketing authorisation for our pancreas powder gastro-resistant capsules, and reaching patients in the UK, marks an important milestone for our company. In Essential Pharma we have found a partner that shares this experience and understands the UK healthcare system, and we look forward to working together for patients in the UK.”

 

The agreement represents a strategic collaboration between two pharmaceutical companies with established expertise in pancreatic enzyme treatments, bringing Nordmark’s product to the UK market through Essential Pharma's specialist healthcare infrastructure.